Clinuvel Profit Dips on Higher Expansion Costs Despite Record Half-Year Revenue

Clinuvel Pharmaceuticals ( (AU:CUV) ) just unveiled an announcement.

Clinuvel Pharmaceuticals reported a 4% rise in half-year revenues to A$36.9 million, driven by increased commercial and Special Access Scheme sales of its flagship drug SCENESSE for erythropoietic protoporphyria and higher interest income on larger cash reserves. Patient demand strengthened, particularly in Europe, while net tangible asset backing per share improved to A$4.93 and cash reserves climbed 4% to A$233 million, underscoring a solid balance sheet.

Despite record December half-year revenues, profit after tax fell 26% to A$10.4 million as operating expenses rose 22% to support business expansion, resulting in a 26% decline in earnings per share to A$0.21. The company maintained its capital-return stance with a fully franked final dividend of 5 cents per share already paid for the prior financial year, signaling continued shareholder focus even as it invests for growth and broader market penetration.

The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.

More about Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals is a specialty biopharmaceutical company focused on photomedicine, developing and commercialising treatments for genetic and skin disorders caused by light and UV exposure. Its lead product, SCENESSE, is approved for erythropoietic protoporphyria and is marketed primarily through commercial sales and special access schemes, with a growing patient base in Europe.

Average Trading Volume: 102,636

Technical Sentiment Signal: Sell

Current Market Cap: A$563.3M

For detailed information about CUV stock, go to TipRanks’ Stock Analysis page.